BRPI9917881B8 - caspase inhibitor compounds, pharmaceutical composition and use of said compounds - Google Patents

caspase inhibitor compounds, pharmaceutical composition and use of said compounds

Info

Publication number
BRPI9917881B8
BRPI9917881B8 BRPI9917881A BRPI9917881A BRPI9917881B8 BR PI9917881 B8 BRPI9917881 B8 BR PI9917881B8 BR PI9917881 A BRPI9917881 A BR PI9917881A BR PI9917881 A BRPI9917881 A BR PI9917881A BR PI9917881 B8 BRPI9917881 B8 BR PI9917881B8
Authority
BR
Brazil
Prior art keywords
compounds
sym
diseases
relates
methods
Prior art date
Application number
BRPI9917881A
Other languages
Portuguese (pt)
Inventor
Grillot Anne-Laure
J Forster Cornelia
J Lauffer David
W Bemis Guy
W Janetka James
P Wilson Keith
W Wannamaker Marion
A Murcko Mark
D Mullican Michael
S Charifson Paul
J Davies Robert
Shi Zhan
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Priority claimed from PCT/US1999/005919 external-priority patent/WO1999047545A2/en
Publication of BRPI9917881B1 publication Critical patent/BRPI9917881B1/en
Publication of BRPI9917881B8 publication Critical patent/BRPI9917881B8/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos. a presente invenção refere-se a novas classes de compostos que são inibidores de caspase, em particular inibidores de enzima de conversão de interleucina-1 beta ("ice"). esta invenção também refere-se a composições farmacêuticas compreendendo estes compostos. os compostos e as composições farmacêuticas desta invenção são particularmente bem adequados para a inibição de atividade de caspase e consequentemente, podem ser vantajosamente usados como agentes contra doenças mediadas por interleucina-1 ("il-1"), apoptose, fator de indução de interferon-<sym> (i-gif), ou interferon-<sym> ("ifn-<sym>"), incluindo doenças inflamatórias, doenças auto-imunes, distúrbios de osso destrutivos, distúrbios proliferativos, doenças infecciosas, e doencas degenerativas. esta invenção também refere-se a métodos para a inibição de atividade de caspase e diminuição de produção de igif e produção de ifn-<sym> e a métodos para o tratamento de doenças mediadas por interferon-<sym>, apoptose, e interleucina-1 usando-se os compostos e as composições desta invenção. esta invenção também refere-se a métodos de preparação dos compostos desta invenção.caspase inhibitor compounds, pharmaceutical composition and use of said compounds. The present invention relates to new classes of compounds which are caspase inhibitors, in particular interleukin-1 beta converting enzyme inhibitors ("ice"). this invention also relates to pharmaceutical compositions comprising these compounds. the compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and therefore can be advantageously used as agents against diseases mediated by interleukin-1 ("il-1"), apoptosis, interferon inducing factor -<sym> (i-gif), or interferon-<sym> ("ifn-<sym>"), including inflammatory diseases, autoimmune diseases, bone destructive disorders, proliferative disorders, infectious diseases, and degenerative diseases. this invention also relates to methods for inhibiting caspase activity and decreasing igif production and ifn-<sym> production and to methods for treating interferon-<sym> mediated diseases, apoptosis, and interleukin- 1 using the compounds and compositions of this invention. this invention also relates to methods of preparing the compounds of this invention.

BRPI9917881A 1998-03-19 1999-03-19 caspase inhibitor compounds, pharmaceutical composition and use of said compounds BRPI9917881B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7877098P 1998-03-19 1998-03-19
BRPI9917842 1999-03-19
PCT/US1999/005919 WO1999047545A2 (en) 1998-03-19 1999-03-19 Inhibitors of caspases

Publications (2)

Publication Number Publication Date
BRPI9917881B1 BRPI9917881B1 (en) 2018-11-21
BRPI9917881B8 true BRPI9917881B8 (en) 2021-05-25

Family

ID=64899143

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9917881A BRPI9917881B8 (en) 1998-03-19 1999-03-19 caspase inhibitor compounds, pharmaceutical composition and use of said compounds

Country Status (1)

Country Link
BR (1) BRPI9917881B8 (en)

Also Published As

Publication number Publication date
BRPI9917881B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
BRPI9909660B8 (en) caspase inhibitor compounds, pharmaceutical composition and use of said compounds
BRPI9612258B8 (en) interleukin-1beta converting enzyme inhibitors as well as pharmaceutical composition.
ATE346085T1 (en) INHIBITORS OF THE INTERLEUKIN-1 BETA CONVERTING ENZYME
PE20001032A1 (en) COMPOSITIONS AND METHODS TO TREAT PULMONARY DISEASES
BR9612191A (en) Interleukin-1beta converting enzyme inhibitors
MEP90508A (en) New pharmaceutical composition
MX9606546A (en) INHIBITORS OF INTERLEUKIN-1&#39;beta&#39; CONVERTING ENZYME.
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
ATE329587T1 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OSTEOPOROSIS AND/OR INFLAMMATORY JOINT DISEASES
AU2901899A (en) 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
WO1999009000A3 (en) Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
BR0310087A (en) Hyaluronic acid injectable solid carriers for application of osteogenic proteins
PT944645E (en) INHIBITORS OF INTERLEUCINA CONVERTER ENZYME 1BETA
YU84102A (en) New dibenzoazulene compounds as tumor necrosis factor inhibitors
BR9807622A (en) Self-regulated inflammatory cell apoptosis by gene therapy
BRPI9917881B8 (en) caspase inhibitor compounds, pharmaceutical composition and use of said compounds
BR0113783A (en) Aqueous composition and methods for increasing the effectiveness of an enzyme-containing composition and for cleaning a medical instrument.
BR0212834A (en) Formulations and use thereof
BR0317445A (en) Compound, pharmaceutical composition, method for treating diseases, and use of a compound
FI982198A0 (en) IL mutein

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 19/03/2019